Oncopeptides to present data from two clinical studies of Ygalo® (melflufen) at American Society of Hematology (ASH), December 9-12.
Stockholm – November 1, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present results from two clinical studies at ASH in Atlanta, US: Final data from the phase II study called O-12-M1 and interim data from the ongoing phase II study called HORIZON. Both studies target late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM).The abstracts submitted for presentation can be found at www.oncopeptides.se/ Investors & media/Presentations with the following headings: O-12-M1 – “First report on median overall survival (OS) and improved median